Loading...
XSTO
ISOFOL
Market cap25mUSD
Jul 10, Last price  
0.83SEK
1D
7.10%
1Q
20.82%
IPO
-96.88%
Name

Isofol Medical AB (publ)

Chart & Performance

D1W1MN
XSTO:ISOFOL chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.75%
Rev. gr., 5y
-11.85%
Revenues
0k
00187,000508,000227,0000037,119,00022,407,00012,797,000721,00000
Net income
-54m
L+24.56%
-10,601,308-10,601,308-40,689,000-64,018,000-72,035,000-83,125,000-161,583,000-188,992,000-200,251,000-159,793,000-37,071,000-43,488,000-54,168,000
CFO
-52m
L+23.70%
0-36,767,000-56,902,000-61,943,000-92,458,000-147,208,000-160,270,000-188,429,000-190,975,000-52,536,000-41,986,000-51,935,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
URL
https://isofolmedical.com/
IPO date
Apr 04, 2017
Employees
3
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT